Equities Analysts Issue Forecasts for Masimo Co.’s Q1 2023 Earnings (NASDAQ:MASI)

Masimo Co. (NASDAQ:MASI – Get Rating) – Equities researchers at Jefferies Financial Group issued their Q1 2023 earnings estimates for shares of Masimo in a research note issued to investors on Wednesday, March 1st. Jefferies Financial Group analyst M. Taylor anticipates that the medical equipment provider will post earnings per share of $0.83 for the quarter. The consensus estimate for Masimo’s current full-year earnings is $4.37 per share. Jefferies Financial Group also issued estimates for Masimo’s Q3 2023 earnings at $1.28 EPS, Q4 2023 earnings at $1.40 EPS, FY2023 earnings at $4.75 EPS and FY2025 earnings at $5.96 EPS.

MASI has been the subject of a number of other reports. Piper Sandler lifted their target price on shares of Masimo from $135.00 to $150.00 and gave the stock a “neutral” rating in a research note on Wednesday. Raymond James lifted their target price on shares of Masimo from $187.00 to $198.00 and gave the stock an “outperform” rating in a research note on Wednesday. Needham & Company LLC lifted their target price on shares of Masimo from $173.00 to $192.00 and gave the stock a “buy” rating in a research note on Wednesday. BTIG Research lifted their target price on shares of Masimo from $180.00 to $195.00 in a research note on Wednesday. Finally, Stifel Nicolaus lifted their target price on shares of Masimo from $164.00 to $170.00 and gave the stock a “buy” rating in a research note on Wednesday, January 11th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $182.00.

Masimo Stock Up 2.3 %

MASI stock opened at $179.92 on Thursday. The firm has a 50 day moving average of $162.27 and a 200 day moving average of $149.00. The stock has a market capitalization of $9.46 billion, a PE ratio of 69.20 and a beta of 0.86. The company has a quick ratio of 1.28, a current ratio of 2.12 and a debt-to-equity ratio of 0.76. Masimo has a 52 week low of $108.89 and a 52 week high of $184.96.

Masimo (NASDAQ:MASI – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The medical equipment provider reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.15. Masimo had a net margin of 7.06% and a return on equity of 18.82%. The business had revenue of $617.00 million for the quarter, compared to analysts’ expectations of $602.49 million. During the same period last year, the business earned $1.21 EPS. The company’s revenue was up 88.4% compared to the same quarter last year.

Hedge Funds Weigh In On Masimo

Several institutional investors have recently made changes to their positions in MASI. IFP Advisors Inc increased its holdings in Masimo by 123.6% in the 3rd quarter. IFP Advisors Inc now owns 161 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 89 shares in the last quarter. Meeder Asset Management Inc. increased its holdings in Masimo by 61.3% in the 2nd quarter. Meeder Asset Management Inc. now owns 221 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 84 shares in the last quarter. Belpointe Asset Management LLC purchased a new stake in Masimo in the 4th quarter worth $38,000. Koshinski Asset Management Inc. purchased a new stake in Masimo in the 3rd quarter worth $711,000. Finally, GHP Investment Advisors Inc. purchased a new stake in Masimo in the 3rd quarter worth $53,000. 87.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Masimo

In other news, CEO Joe E. Kiani bought 7,040 shares of the business’s stock in a transaction dated Thursday, December 15th. The stock was purchased at an average cost of $144.79 per share, with a total value of $1,019,321.60. Following the acquisition, the chief executive officer now directly owns 46,818 shares in the company, valued at $6,778,778.22. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 9.70% of the company’s stock.

About Masimo

(Get Rating)

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories.